Parasite Adhesion Receptor Emerges as Drug Target in Schistosomiasis Study

Schistosomiasis, a parasitic worm disease that afflicts hundreds of millions of people across Africa, Asia and South America, has long resisted the kind of molecular scrutiny that has transformed treatment for other tropical diseases. Now, a team of researchers working across Ghana, Nigeria, Namibia, the United Kingdom and Germany has turned to cutting-edge computational structural biology to interrogate one of the most enigmatic molecular machines in the blood fluke Schistosoma mansoni: its integrins. In a study published in BMC Genomics, the group reports that a specific pairing of integrin subunits, dubbed Smα1 and Smβ1, emerges as the most plausible receptor candidate capable of recognizing RGD-containing ligands, the same molecular handshake that human cells use to grip their surrounding matrix.

Integrins are heterodimeric adhesion receptors composed of an alpha and a beta chain, and they sit embedded in cell membranes across virtually all metazoan life. Their job is deceptively simple but biologically profound: they anchor cells to the extracellular matrix, transmit mechanical forces, and relay chemical signals from outside the cell to the interior. In humans, integrins are implicated in everything from wound healing to cancer metastasis, and they have become prized pharmaceutical targets. In parasitic helminths, however, integrin homologues have been identified at the sequence level for years, yet their three-dimensional organization and ligand-binding behavior remained largely uncharted territory. The new study set out to close that gap using an integrative computational pipeline rather than laboratory experiments alone.

The researchers began with comparative sequence analysis across medically important Schistosoma species, searching for conserved integrin genes in the genomes of the parasites. Their screen revealed a striking asymmetry. On the beta side, a single highly conserved orthologue, which they named Smβ1, was present and well preserved across species, suggesting that it performs an essential function that evolution has been reluctant to alter. On the alpha side, the picture was more complicated: four divergent alpha-integrin subunits were identified, each carrying distinctive sequence features that hinted at different evolutionary histories and potentially different binding partners. This combination of one conserved beta chain and several variable alpha chains mirrors the architecture of integrin systems in other organisms, where the beta subunit provides the core ligand-binding machinery and the alpha subunit tunes its specificity.

To move from sequences to structures, the team deployed three independent protein-structure prediction engines: AlphaFold3, RoseTTAFold and trRosetta. Convergent predictions from these tools showed that the betaI-containing region of Smβ1 retains the characteristic integrin fold that has been described in exquisite detail for human receptors. Critically, the model preserved the three canonical metal-coordination sites that define integrin ligand recognition: the metal-ion-dependent adhesion site, known as MIDAS, which directly coordinates the acidic residue of incoming ligands; the adjacent ADMIDAS site, which allosterically regulates the receptor’s activation state; and the synergistic metal-binding site, or SyMBS, which helps stabilize the ligand-bound conformation. The retention of these features in a parasite receptor is significant because it suggests that the fundamental chemistry of integrin-ligand engagement, dependent on metal ions bridging receptor and ligand, has been conserved across hundreds of millions of years of evolution separating flatworms from vertebrates.

With individual subunit structures in hand, the next challenge was determining which alpha chain pairs with Smβ1. Integrin function depends entirely on the correct heterodimer assembly, and predicting which of the four candidate alpha subunits forms a stable, functional complex with the beta chain is a problem that sequence similarity alone cannot solve. The researchers therefore constructed an integrated structural benchmarking framework that scored each candidate assembly across multiple independent dimensions: conservation of the overall fold, stereochemical and backbone quality of the predicted model, VoroMQA-based assessment of Voronoi packing density, the architecture of the alpha-beta interface itself, the buried surface area at the interface, and separate interface-context analyses designed to catch artifacts that single metrics might miss.

When the scores were tallied, one pairing stood out. Smα1 in combination with Smβ1 was ranked as the leading heterodimer candidate, while Smα3 paired with Smβ1 remained a structurally plausible alternative that could not be excluded. This ranking mattered because the identity of the alpha subunit shapes the geometry of the ligand-binding pocket that forms at the interface between the two chains. The team then subjected both candidate assemblies to ligand-challenge modelling, docking RGD-containing peptides into the predicted binding sites and comparing the resulting interaction geometries against a human α5β1 integrin benchmark whose RGD-bound structure is experimentally established.

The results were revealing. Smα1/Smβ1 more readily reproduced the coupled interaction pattern seen in the human benchmark, in which the arginine residue of the RGD motif anchors to a defined pocket on the alpha subunit while the aspartate residue coordinates the MIDAS metal ion on the beta subunit. Smα3/Smβ1, by contrast, was less consistent in reproducing this canonical geometry. Across expanded ensembles of ligand structures, canonical and cyclic RGD-containing peptides preferentially adopted RGD-like interaction geometries with the receptor, whereas an RGE mutant peptide, in which the aspartate is replaced by glutamate, and various non-RGD control peptides showed reduced or absent canonical interaction features. This specificity pattern is exactly what one would expect from a genuine RGD-recognizing integrin, since the RGE substitution is a classic experimental control that abolishes integrin binding in well-characterized systems.

Molecular dynamics simulations provided the temporal dimension that static docking cannot capture. In trajectories running 100 and 200 nanoseconds, the canonical RGD peptide remained within a comparatively restricted conformational regime associated with the receptor, suggesting a stable engagement, while the RGE mutant underwent greater displacement and induced more structural mobility in the contact site. Complementary MM/GBSA energetic analysis computed over the 200-nanosecond trajectory frames further supported more favourable energetic compatibility for RGD than for RGE. Together, these dynamic and energetic measures reinforce the picture painted by the docking experiments: the Smα1/Smβ1 complex behaves, under modelled conditions, like a receptor that genuinely prefers RGD ligands over near-identical decoys.

Beyond ligand binding, the study ventured into signaling territory with an exploratory network analysis using the STRING database. This placed Smβ1 within a predicted adhesome-like network that includes the integrin-linked kinase, or ILK, together with its PINCH and Parvin partners and kinase-associated components. In animal cells, the ILK-PINCH-Parvin complex is a central scaffold of the integrin adhesion complex, coupling receptors at the membrane to the actin cytoskeleton and to signaling pathways. Finding a predicted network of this composition around a schistosome beta integrin raises the possibility that the parasite uses signaling machinery broadly analogous to that of its host, which carries implications for how the worm adheres to and navigates host tissues during its complex life cycle.

The authors are careful to frame their conclusions as hypothesis-generating rather than definitive. Every result in the study derives from computational prediction and simulation, and the models, however sophisticated, remain subject to experimental validation. The paper explicitly presents its findings as experimentally testable hypotheses concerning alpha-beta pairing, metal-dependent ligand recognition and integrin-associated signaling in schistosomes. Still, the implications are considerable. If Smα1/Smβ1 is confirmed as a functional RGD-recognizing receptor, it would open a new window on how S. mansoni interacts with host extracellular matrix during infection, and it would offer a structurally characterized parasite-specific target whose human counterparts are already druggable, potentially accelerating the search for much-needed new therapies against a disease for which treatment still relies almost entirely on a single drug, praziquantel.

Subject of Research: Structural and ligand-binding characterization of Schistosoma mansoni integrin receptors

Article Title: Computational structural analysis of Schistosoma integrins supports Smα1/Smβ1 as an RGD-compatible receptor candidate

Article References: Adu, E. A., Owoloye, A., Shakela, N., Aziz, R. N., Boakye, A. O., Acheampong, E., Nyarko, E. N. Y., Adu-Amoah, L., Afum-Adjei Awuah, A., Amuasi, J. H., & Obirikorang, C. (2026). Computational structural analysis of Schistosoma integrins supports Smα1/Smβ1 as an RGD-compatible receptor candidate. BMC Genomics. https://doi.org/10.1186/s12864-026-13429-9

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13429-9

Keywords: Schistosoma mansoni, schistosomiasis, integrins, Smβ1, Smα1, RGD motif, AlphaFold3, molecular dynamics, MIDAS, protein-ligand interactions, host-parasite interactions, structural genomics